Introduction
============

The first part of this review ([Ekins *et al*., 2007](#bib33){ref-type="other"}) has briefly described the history and development of a field that can be globally referred to as *in silico* pharmacology. This included the development of methods and databases, quantitative structure--activity relationships (QSARs), similarity searching, pharmacophores, homology models and other molecular modelling, machine learning, data mining, network analysis and data analysis tools that all use a computer. We have also previously introduced how some of these methods can be used for virtual ligand- and target-based screening and virtual affinity profiling. In this second part of the review, we will greatly expand on the applications of these methods to many different target proteins and complex properties, and discuss the pharmacological space covered by some of these *in silico* efforts. In the process, we will detail the success of *in silico* methods at identifying new pharmacologically active molecules for many targets and highlight the resulting enrichment factors when screening active drug-like databases. We will finally discuss some of the advantages and disadvantages of *in silico* methods with respect to *in vitro* and *in vivo* methods for pharmacology research.

Pharmacological space covered
=============================

The applicability of computational approaches to ligand and target space in which a lead molecule against one gene family member is used for another similar target (termed chemogenomics) ([Morphy *et al*., 2004](#bib103){ref-type="other"}; [Sharom *et al*., 2004](#bib131){ref-type="other"}), will be discussed thoroughly in an upcoming review in this journal from Didier Rognan (personal communication) and will be only briefly addressed here. However, there have been several attempts to establish relationships between molecular structure and broad biological activity and effects that should be considered (see also section 2.3.1 in [Ekins *et al*. (2007)](#bib33){ref-type="other"}) ([Kauvar *et al*., 1995](#bib71){ref-type="other"}, [1998b](#bib73){ref-type="other"}; [Kauvar and Laborde, 1998a](#bib72){ref-type="other"}). For example, the work of [Fliri *et al*. (2005b)](#bib42){ref-type="other"} presented the biological spectra for a cross-section of the proteome. Using hierarchical clustering of the spectra similarity enabled a relationship between structure and bioactivity to be constructed. This work was extended to identify agonist and antagonist profiles at various receptors, correctly classifying similar functional activity in the absence of drug target information ([Fliri *et al*., 2005c](#bib43){ref-type="other"}). Interestingly, using IC~50~ data as affinity fingerprints did not identify functional activity similarities between molecules as this approach was suggested to introduce a pharmacophoric bias ([Fliri *et al*., 2005c](#bib43){ref-type="other"}). A similar probabilistic approach has also been applied by the same authors to link adverse effects for drugs (obtained from the drug labelling information) with biological spectra. For instance, clustering molecules by side effect profile showed that similar molecules had overlapping profiles, in the same way that they had similar biological spectra, linking preclinical with clinical effects ([Fliri *et al*., 2005a](#bib41){ref-type="other"}). This work offers the intriguing possibility of predicting a biospectra profile, possible functional activity and a side effect profile for a new molecule based on similarity alone. However, confidence in this approach would be greatly enhanced by further prospective testing with a large test set of drug-like molecules not used to generate the underlying signature database.

A second group also from Pfizer presented a global mapping of pharmacological space and in particular focused on a polypharmacology network of molecules with activity against multiple proteins ([Paolini *et al*., 2006](#bib115){ref-type="other"}). They have additionally generated Bayesian binary models (for molecules active at \<10 *μ*[M]{.smallcaps} or inactive) for 698 targets using over 200 000 molecules with biological data (from their in-house collection and the literature), suggesting that they would be useful for predicting primary pharmacology. Assessment of 617 approved oral drugs in two-dimensional (2D) molecular property space (molecular weight versus cLogP) showed that many of them had cLogP \>5 and MW \>500. In spite of this, their associated targets were potentially druggable but had yet to realize their potential ([Paolini *et al*., 2006](#bib115){ref-type="other"}). Perhaps this work needs to be combined with that of Fliri and others for its true potential to be realized, to enable simultaneous understanding and prediction of target, proteomic, functional activity and side effects. A recent analysis using 48 molecular 2D descriptors followed by principal component (PCA) of over 12 000 anticancer molecules representing cancer medicinal chemistry space, showed that they populated a different space broader than hit-like space and orally available drug-like space. This would indicate that in order to find molecules for anticancer targets in commercially available databases, different rules are required other than those widely used for drug-likeness, as they may unfortunately filter out possible clinical candidates ([Lloyd *et al*., 2006](#bib91){ref-type="other"}).

Methods to predict the potential biological targets for molecules from just chemical structure have been attempted by using different approaches to those already described above. For example, one study used probabilistic neural networks with 24 atom-type descriptors to classify 799 molecules from the MDL Drug Data Reports (MDDR) database with activity against one of the seven targets (G protein-coupled receptors (GPCRs), kinases, enzymes, nuclear hormone receptors and zinc peptidases) with excellent training, testing and prediction statistics ([Niwa, 2004](#bib109){ref-type="other"}). Twenty-one targets related to depression were selected and molecules from the MDDR database were used to create support vector machine (SVM) classification models from atom-type descriptors ([Lepp *et al*., 2006](#bib86){ref-type="other"}). These models had satisfactory predictions and recall values between 45 and 90%, the molecules recovered being on average of low molecular weight (\<300) and some were active against more than one model. It was suggested that general SVM filters would be useful for virtual screening owing to their speed. Others have used similarity searching of the MDDR database against small numbers of reference inhibitors for several different targets and were able to show variable enrichment factors that were greater than random ([Hert *et al*., 2004](#bib59){ref-type="other"}). The structure-based alternative to understanding small molecule--protein interactions is to flexibly dock molecules into multiple proteins. A representative of this inverse docking approach is INVDOCK, which was recently applied for identifying potential adverse reactions using a database of 147 proteins related to toxicities (DART). This method has been recently demonstrated with 11 marketed anti-HIV drugs resulting in reasonable accuracy against the DNA polymerase beta and DNA topoisomerase I ([Ji *et al*., 2006](#bib67){ref-type="other"}).

The public availability of data on drugs and drug-like molecules may make the analyses described above possible for scientists outside the private sector. For example, chemical repositories such as DrugBank (<http://redpoll.pharmacy.ualberta.ca/drugbank/>) ([Wishart *et al*., 2006](#bib164){ref-type="other"}), PubChem (<http://pubchem.ncbi.nlm.nih.gov/>), KiDB (<http://kidb.bioc.cwru.edu/>) ([Roth *et al*., 2004](#bib122){ref-type="other"}; [Strachan *et al*., 2006](#bib147){ref-type="other"}) and others consist of a wealth of target and small molecule data that can be mined and used for computational pharmacology approaches. Although much of the *in silico* pharmacology research to date has been focused on human targets, many of these databases contain data from other species that would also be useful for understanding species differences and promoting discovery of molecules for animal healthcare as well as assisting in understanding the significance of toxicological findings for chemicals released into the environment.

Examples of *in silico* pharmacology
------------------------------------

To exhaustively describe all of the proteins that have been computationally modelled under the auspices of *in silico* pharmacology would be impossible in the confines of this review. Therefore, we will briefly overview the types of proteins that have been modelled and the methods used (see below and [Table 1](#tbl1){ref-type="table"}). In addition, we will focus on and describe particular pharmacological applications with regard to virtual screening where novel ligands have been identified. The reader is highly encouraged to study an extensive review of success stories in computer-aided design, which covers a large number of proteins that have been targets for all manner of *in silico* methods ([Kubinyi, 2006](#bib81){ref-type="other"}), as well as other reviews that have dealt with the successes of individual methods ([Fujita, 1997](#bib45){ref-type="other"}; [Kurogi and Guner, 2001a](#bib83){ref-type="other"}; [Guner *et al*., 2004](#bib56){ref-type="other"}). As described previously, computational approaches for drug discovery and development may have more impact if integrated ([Swaan and Ekins, 2005](#bib148){ref-type="other"}) and we have previously attempted to show that computational methods have been broadly applied to virtually all important proteins in absorption, distribution, metabolism, excretion and toxicity (ADME/Tox) ([Ekins and Swaan, 2004b](#bib36){ref-type="other"}). The qaim of this paper is to provide an up-to-date review of all proteins and protein families addressed through current state-of-the-art *in silico* pharmacology methods.

### Drug target examples

*Enzymes:*The ubiquitin regulatory pathway, in which ubiquitin is conjugated and deconjugated with substrate proteins, represents a source of many potential targets for modulation of cancer and other diseases ([Wong *et al*., 2003](#bib166){ref-type="other"}). The recent crystal structure of a mammalian de-ubiquitinating enzyme HAUSP, which specifically de-ubiquitinates the ubiquitinated p53 protein, may also assist in drug development despite the peptidic nature of its substrate ([Hu *et al*., 2002](#bib64){ref-type="other"}). Novel non-peptidic inhibitors of the protease ubiquitin isopeptidase, which not only de-ubiquitinates p53 but other general ubiquitinated proteins as well, were discovered recently using a simple pharmacophore-based search of the National Cancer Institute (NCI) database ([Mullally *et al*., 2001](#bib105){ref-type="other"}; [Mullally and Fitzpatrick, 2002](#bib104){ref-type="other"}). These inhibitors had IC~50~ values in the low micromolar range and caused cell death independent of the tumour suppressor p53, which is mutated in greater than 50% of all cancers (hence, p53 inhibition *per se* may not represent an optimal target for modulation). The ubiquitin isopeptidase inhibitors shikoccin, dibenzylideneacetone, curcumin and the more recently described punaglandins from coral indicate that a sterically accessible *α*,*β*-unsaturated ketone is essential for bioactivity ([Verbitski *et al*., 2004](#bib157){ref-type="other"}). All these molecules represent valuable leads for further chemical optimization.

Aromatase (cytochrome *P*450 (CYP)19) is a validated target for breast cancer. A ligand-based pharmacophore was generated with three non-steroidal inhibitors. This model could recognize known inhibitors from an in-house library and was further refined by the addition of molecular shape. The model was further used to search the NCI database and molecules were scored with a quantitative Catalyst Hypo-Refine (Accelrys Inc., San Diego, CA, USA) model generated with 16 molecules. The hits were also filtered with other pharmacophores for toxicity-related proteins, before testing. Two out of the three compounds were ultimately found to be micromolar inhibitors ([Schuster *et al*., 2006](#bib127){ref-type="other"}).

A structure-based Catalyst pharmacophore was developed for acetylcholine esterase, which was subsequently used to search a natural product database. The strategy identified scopoletin and scopolin as hits and were later shown to have moderate *in vivo* activity ([Rollinger *et al*., 2004](#bib121){ref-type="other"}). The same database was also screened against cyclooxygenase (COX)-1 and COX-2 structure-based pharmacophores, leading to the identification of known COX inhibitors. These represent examples where a combination of ethnopharmacological and computational approaches may aid drug discovery ([Rollinger *et al*., 2005](#bib120){ref-type="other"}).

A combined ligand-based and structure-based approach was taken to gaining structural insights into the human 5-lipoxygenase (LOX). A Catalyst qualitative HipHop model was created with 16 different molecules that resulted in a five-feature pharmacophore. A homology model of the enzyme was based on two soybean LOX enzymes and one rabbit LOX enzyme. Molecular docking was then used to update and refine the pharmacophore to a four-feature model that could also be visualized in the homology model of 5-LOX. As a result of these models, amino-acid residues in the binding site were suggested as targets for site-directed mutagenesis while virtual screening with the pharmacophore had suggested compounds with a phenylthiourea or pyrimidine-5-carboxylate group for testing ([Charlier *et al*., 2006](#bib16){ref-type="other"}). Homology models for the human 12-LOX and 15-LOX have also been used with the flexible ligand docking programme Glide (Schrödinger Inc.) to perform virtual screening of 50 000 compounds. Out of 20 compounds tested, 8 had inhibitory activity and several were in the low micromolar range ([Kenyon *et al*., 2006](#bib75){ref-type="other"}).

More than 30 years of research on renin have not been enough to deliver a marketed drug that inhibits this enzyme. In spite of this, renin remains an attractive yet elusive target for hypertension ([Fisher and Hollenberg, 2001](#bib39){ref-type="other"}; [Stanton, 2003](#bib143){ref-type="other"}). In this respect, application of structure-based design leads to the identification of new non-peptidic inhibitors of human renin. These molecules include aliskiren ([Rahuel *et al*., 2000](#bib119){ref-type="other"}; [Torres *et al*., 2003](#bib154){ref-type="other"}), piperidines, including Ro-0661168 ([Guller *et al*., 1999](#bib55){ref-type="other"}; [Oefner *et al*., 1999](#bib113){ref-type="other"}; [Vieira *et al*., 1999](#bib158){ref-type="other"}), and related 3,4-disubstituted piperidines ([Marki *et al*., 2001](#bib100){ref-type="other"}). Interestingly, these piperidines bind to and stabilize a different conformer of the protein termed 'open renin\' ([Bursavich and Rich, 2002](#bib11){ref-type="other"}), whereas aliskiren binds to 'closed renin\'. Since these latter structure-based design efforts, there have been remarkably very few published attempts at computer-aided design of novel renin inhibitors. A single early QSAR was derived for a series of chain-modified peptide analogues of angiotensinogen. The activity of these molecules was found to correlate with Kier\'s first-order molecular connectivity index descriptor and molecular weight but not with lipophilicity as measured by logP ([Khadikar *et al*., 2005](#bib76){ref-type="other"}). Another computational method for renin drug discovery used the *de novo* design software GrowMol, which could apparently regenerate 3,4-disubstituted piperidines in 1% of the grown structures ([Bursavich and Rich, 2002](#bib11){ref-type="other"}). An attempt to use a Catalyst pharmacophore to discover new renin inhibitors was described in the early 1990s ([Van Drie, 1993](#bib156){ref-type="other"}). Several novel molecules from the Pomona database (an early three-dimensional (3D) molecule database) were found that mapped to a renin pharmacophore but apparently were not tested *in vitro*. More recently, a LigandFit docking study with a crystal structure of the 'open renin\' form was able to detect 10 known inhibitors seeded in a library of 1000 compounds within the top 8.4% when using a consensus scoring function. Four examples of high-scoring compounds that were not tested as inhibitors fulfilled the pharmacophore derived from the X-ray data, consisting of four hydrophobes, a hydrogen bond donor or positive ionizable feature as well as excluded volumes ([Krovat and Langer, 2004](#bib80){ref-type="other"}). Another study has used similarity searching of the MDDR database (for over 100 000 compounds) using 10 renin inhibitors and was able to produce enrichment factors that were 17-fold greater than random ([Hert *et al*., 2004](#bib59){ref-type="other"}). Genetic algorithms have also been used for class discrimination between renin inhibitors and non-inhibitors in a subset of the MDDR using a small number of interpretable descriptors. Among them, amide bond count, molecular weight and hydrogen bond donor counts were found to be much higher in renin inhibitors ([Ganguly *et al*., 2006](#bib49){ref-type="other"}). The recent publications on novel renin inhibitors represent a considerable amount of new information that could be used for further QSAR model development and database searching efforts in order to derive novel starting scaffolds for optimization.

Cathepsin D is an aspartic protease found mainly in lysosomes, which may have a role in *β*-amyloid precursor protein release and hence may well be a target for Alzheimer\'s disease. Cathepsin D may also be elevated in breast cancer and ovarian cancer hence a means to modulate this activity could be beneficial in these diseases. There has been a brief overview of Cathepsin D in a comprehensive review of protease inhibitors ([Leung *et al*., 2000](#bib87){ref-type="other"}). A combination of a structure-based design algorithm and combinatorial chemistry has been successfully applied to finding novel molecules for Cathepsin D in the nanomolar range ([Kick *et al*., 1997](#bib77){ref-type="other"}). Structures based on pepstatin (a 3.8 pM inhibitor ([Baldwin *et al*., 1993](#bib5){ref-type="other"})) yielded a 6--7% hit rate. These molecules were tested *in vitro* using hippocampal slices and were shown to block the formation of hyperphosphorylated Tau fragments ([Bi *et al*., 2000](#bib8){ref-type="other"}). There have been relatively few computational studies to date on Cathepsin D and other related aspartic proteases such as renin and *β*-secretase. One study has used molecular dynamics and free energy analyses (MM-PBSA) of Cathepsin D inhibitor interactions to suggest new substitutions that may improve binding ([Huo *et al*., 2002](#bib66){ref-type="other"}). A genetic algorithm-based *de novo* design tool, ADAPT has also been used to rediscover active Cathepsin D molecules, by placing key fragments in the correct positions ([Pegg *et al*., 2001](#bib116){ref-type="other"}). Computational models may aid in the selection of novel ligands for protease inhibition that are non-peptidic and selective. Using the structural features of eight published inhibitors for Cathepsin D ([Huo *et al*., 2002](#bib66){ref-type="other"}), a five-feature pharmacophore was derived consisting of three hydrophobes and two hydrogen bond acceptors (*r*=0.98). This pharmacophore was used to search a molecule database and selected 10 molecules out of 11 441 present. In contrast, a similarity search at the 95% level using ChemFinder (CambridgeSoft, Cambridge, MA, USA) suggested 16 different molecules. All of these were selected for testing *in vitro*. The pharmacophore produced four hits (40% hit rate) and the similarity search generated five hits (31% hit rate), where at least one replicate showed greater than 40% inhibition ([Ekins *et al*., 2004a](#bib30){ref-type="other"}). *In silico* evaluation of the ADME properties for all active compounds estimated that the molecules would be well absorbed, although some were predicted to have solubility and CYP2D6 inhibition problems.

Pharmacophore- and structure-based approaches have been used to optimize an acyl urea hit for human glycogen phosphorylase. A Catalyst HypoGen five-feature pharmacophore was developed and used to guide further analogue synthesis. These compounds showed a good correlation with prediction (*r*=0.71). An X-ray structure for one molecule was used to confirm the predicted binding conformation. Ultimately, a comparative molecular field analysis (CoMFA) model was generated with all molecules synthesized and was found to be complementary to the X-ray structure. The outcome of this study was a molecule with good cellular activity that could inhibit blood glucose levels *in vivo* in rat ([Klabunde *et al*., 2005](#bib78){ref-type="other"}).

The human sirtuin type 2, a target for controlling aging and some cancers, deacetylates *α*-tubulin and has been crystallized at high resolution. This structure has been used for docking the Maybridge database and returned a small hit list from which 15 compounds were tested and 5 showed activity at the micromolar level ([Tervo *et al*., 2004](#bib150){ref-type="other"}).

Catechol *O*-methyltransferase is a target for Parkinson\'s disease and there is currently a crystal structure of the enzyme that has been used to generate a homology model of the human enzyme. This model was used to dock with FlexX software several catechins from tea and understand the structure-activity relationship (SAR) for these molecules and their metabolites, which had been tested *in vitro*. Ultimately, the combination of *in vitro* and computational work indicated that the galloyl group on catechins, the distance between Lys 144 on the enzyme, and the reacting catecholic hydroxy group were important for inhibition ([Chen *et al*., 2005](#bib17){ref-type="other"}).

### Kinases:

The kinases represent an attractive family of over 500 targets for the pharmaceutical industry, with several drugs approved recently. Kinase space has been mapped using selectivity data for small molecules to create a chemogenomic dendrogram for 43 kinases that showed the highly homologous kinases to be inhibited similarly by small molecules ([Vieth *et al*., 2004](#bib159){ref-type="other"}). Virtual screening methods have been applied quite widely for kinases to date ([Fischer, 2004](#bib38){ref-type="other"}). The structure-based design method has produced new potent inhibitors of CDK1 starting from the highly similar apo CDK2 and the positioning of olomoucine. A few amino-acid residues were mutated to conform to the CDK1 sequence. MacroModel was used to energy minimize molecules in the ATP pocket and visual inspection suggested points for molecular modification on the ligand. Very quickly, design efforts guided ligand optimization to improve activity from 4.5 *μ*[M]{.smallcaps} to 25 n[M]{.smallcaps} ([Furet *et al*., 2000](#bib47){ref-type="other"}). A more recent CDK1/cyclin B homology model was also used to manually dock ligands, which enabled progression from alsterpaullone with an IC~50~ of 35 n[M]{.smallcaps} to a derivative with an IC~50~ of 0.23 n[M]{.smallcaps} ([Kunick *et al*., 2005](#bib82){ref-type="other"}).

A structure-based *in silico* screening method was pursued for the Syk C-terminal SH2 domain using DOCK to find low molecular weight fragments for each binding site with millimolar binding affinity. The fragments were then linked to result in molecules in the 38--350 *μ*[M]{.smallcaps} range, which is a starting point for further lead optimization ([Niimi *et al*., 2001](#bib108){ref-type="other"}).

A pseudoreceptor model was built with a set of 27 epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors with the flexible atom receptor model method. The top 15 models created had high *r*^2^ and *q*^2^ and were also validated with a six-molecule test set. The pseudoreceptor was also in accord with a crystal structure of CDK2 ([Peng *et al*., 2003](#bib117){ref-type="other"}).

Virtual screening using DOCK with the crystal structure of the Lck SH2 domain was used to screen two million commercially available molecules. Extensive filtering was required to result in a manageable hit list using molecular weight and diversity. Out of 196 compounds tested *in vitro*, 34 were inhibitory at 100 *μ*[M]{.smallcaps}, while 2 had activities of 10 and 40 *μ*[M]{.smallcaps}. Fluorescence titrations of some of these compounds suggested the *K*~D~ values were in the low micromolar range ([Huang *et al*., 2004](#bib65){ref-type="other"}). The same group also took a similar approach to discover inhibitors of ERK2 by screening 800 000 compounds computationally and testing *in vitro* 80 of them ([Hancock *et al*., 2005](#bib57){ref-type="other"}). Five of these molecules inhibited cell proliferation and two were shown by fluorescence titration to bind ERK2 with *K*~D~ values, which were in the low micromolar range. In both cases, docking of the active molecules suggested orientations for verification by X-ray crystallography ([Hancock *et al*., 2005](#bib57){ref-type="other"}).

The Ligand Scout method was used with BCR-ABL tyrosine kinase to find STI-571 (imatinib, Gleevec) in a single and multiple conformation database ([Wolber and Langer, 2005](#bib165){ref-type="other"}). A structurally related three-substituted benzamidine derivative of STI-571 was suggested by structure-based design and when manually docked into the binding site and energy minimized, it was shown to form favourable interactions with a hydrophobic pocket.

CK2 and PKD are part of the COP9 signalosome and can control stability of p53 and c-Jun, which are important for tumour development. Curcumin, besides being an inhibitor of ubiquitin isopeptidase ([Mullally *et al*., 2001](#bib105){ref-type="other"}; [Mullally and Fitzpatrick, 2002](#bib104){ref-type="other"}) and activator protein-1 ([Tsuchida *et al*., 2006](#bib155){ref-type="other"}), also inhibits CK2 and PKD. Using curcumin and emodin as reference structures against which a database of over a million molecules was screened by means of 2D and 3D similarity searches retrieved 35 molecules. Among them, seven possessed inhibitory activity. For example, piceatannol was more potent than curcumin against both CK2 and PKD, with IC~50~ values of 2.5 and 0.5 *μ*[M]{.smallcaps}, respectively ([Fullbeck *et al*., 2005](#bib46){ref-type="other"}). Obviously, these examples suggest there has been some success in finding active molecules for kinases, but interestingly in few of these studies is selectivity toward other kinases accounted for. Ultimately, for therapeutic success activity toward several kinases (but selectivity toward others) may be required.

### Drug-metabolizing enzymes and transporters:

Mathematical models describing quantitative structure--metabolism relationships were pioneered by [Hansch *et al*. (1968)](#bib58){ref-type="other"} using small sets of similar molecules and a few molecular descriptors. Later, Lewis and co-workers provided many QSAR and homology models for the individual human CYPs ([Lewis, 2000](#bib88){ref-type="other"}). As more sophisticated computational modelling tools became available, we have seen a growth in the number of available models ([de Groot and Ekins, 2002b](#bib22){ref-type="other"}; [de Graaf *et al*., 2005](#bib19){ref-type="other"}; [de Groot, 2006](#bib20){ref-type="other"}) and the size of the data sets they encompass. Some more recent methods are also incorporating water molecules into the binding sites when docking molecules into these enzymes and these may be important as hydrogen bond mediators with the binding site amino acids ([Lill *et al*., 2006](#bib89){ref-type="other"}). Docking methods can also be useful for suggesting novel metabolites for drugs. A recent example used a homology model of CYP2D6 and docked metoclopramide as well as 19 other drugs to show a good correlation between IC~50~ and docking score *r*^2^=0.61 ([Yu *et al*., 2006](#bib167){ref-type="other"}). A novel aromatic *N*-hydroxy metabolite was suggested as the major metabolite and confirmed *in vitro*. Now that several crystal structures of the mammalian CYPs are available, they have been found to compare quite favourably to the prior computational models ([Rowland *et al*., 2006](#bib124){ref-type="other"}). However, for some enzymes like CYP3A4, where there is both ligand and protein promiscuity, there may be difficulty in making reliable predictions with some computational approaches such as docking with the available crystal structures ([Ekroos and Sjogren, 2006](#bib37){ref-type="other"}). Hence, multiple pharmacophores or models may be necessary for this and other enzymes ([Ekins *et al*., 1999a](#bib31){ref-type="other"}, [1999b](#bib32){ref-type="other"}), as it has been indicated by others more recently ([Mao *et al*., 2006](#bib99){ref-type="other"}).

The UDP-glucuronosyltransferases are a class of versatile enzymes involved in the elimination of drugs by catalysing the conjugation of glucuronic acid to substrates bearing a suitable functional group, so called phase II enzymes. There have been numerous QSAR and pharmacophore models that have been generated with relatively small data sets for rat and human enzymes. The pharmacophores for the human UGT1A1, UGT1A4 and UGT1A9 all have in common two hydrophobes and a glucuronidation feature, while UGT1A9 has an additional hydrogen bond acceptor feature ([Smith *et al*., 2004](#bib140){ref-type="other"}; [Sorich *et al*., 2004](#bib141){ref-type="other"}). Sulfotransferases, a second class of conjugating enzymes, have been crystallized ([Dajani *et al*., 1999](#bib18){ref-type="other"}; [Gamage *et al*., 2003](#bib48){ref-type="other"}) and a QSAR method has also been used to predict substrate affinity to SULT1A3 ([Dajani *et al*., 1999](#bib18){ref-type="other"}). To the best of our knowledge, computational models for other isozymes have not been developed. In general, conjugating enzymes have generally been infrequently targeted for *in silico* models. Perhaps because of a paucity of *in vitro* data and limited diversity of molecules tested, they have been less widely applied in industry.

The computational modelling of drug transporters has been thoroughly reviewed by numerous groups ([Zhang *et al*., 2002a](#bib168){ref-type="other"}, [2002b](#bib169){ref-type="other"}; [Chang and Swaan, 2005](#bib15){ref-type="other"}) and will not be addressed here in detail. Various transporter models have also been applied to database searching to discover substrates and inhibitors ([Langer *et al*., 2004](#bib85){ref-type="other"}; [Pleban *et al*., 2005](#bib118){ref-type="other"}; [Chang *et al*., 2006b](#bib14){ref-type="other"}) and increase the efficiency of *in vitro* screening ([Chang *et al*., 2006a](#bib13){ref-type="other"}) or enrichment over random screening. A pharmacophore model of the Na^+^/[D]{.smallcaps}-glucose co-transporter found in renal proximal tubules was derived indirectly using phlorizin analogues with the DISCO programme to superpose molecules. This enabled an estimate of the size of the binding site to be obtained. In contrast to more recent studies with transporter pharmacophores, this model was not tested or used for database searching ([Wielert-Badt *et al*., 2000](#bib162){ref-type="other"}).

### Receptors:

There are more than 20 different families of receptors that are present in the plasma membrane, altogether representing over 1000 proteins of the receptorome ([Strachan *et al*., 2006](#bib147){ref-type="other"}). Receptors have been widely used as drug targets and they have a wide array of potential ligands. However, it should be noted that to date we have only characterized and found agonists and antagonists for a small percentage of the receptorome. The *α*-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor is central to many central nervous system (CNS) pathologies and ligands have been synthesized as anticonvulsants and neuroprotectants. There is currently no 3D structure information and therefore a four-point Catalyst HIPHOP pharmacophore was developed with 14 antagonists. This was then used to search the Maybridge database and select eight compounds for testing of which six of these were found to be active *in vivo* as anticonvulsants ([Barreca *et al*., 2003](#bib6){ref-type="other"}).

Serotonin plays a role in many physiological systems, from the CNS to the intestinal wall. Along with its many receptors, it has a major developmental function regulating cardiovascular morphogenesis. The 5-HT~2~ receptor family are G protein-coupled 7-transmembrane spanning receptors with 5-HT~2B~ expressed in cardiovascular, gut, brain tissues, as well as human carcinoid tumors ([Nebigil *et al*., 2000](#bib106){ref-type="other"}). In recent years, this receptor has been implicated in the valvular heart disease defects caused by the now banned 'fen-phen\' treatment of patients. The primary metabolite, norfenfluramine, potently stimulates 5-HT~2B~ ([Fitzgerald *et al*., 2000](#bib40){ref-type="other"}; [Rothman *et al*., 2000](#bib123){ref-type="other"}). Computational modelling of this receptor has been limited to date. A traditional QSAR study used a small number of tetrahydro-*β*-carboline derivatives as antagonists of the rat 5-HT~2B~ contractile receptor in the rat stomach fundus ([Singh and Kumar, 2001](#bib137){ref-type="other"}). A 3D-QSAR with GRID-GOLPE using 38 (aminoalkyl)benzo and heterocycloalkanones as antagonists of the human receptor resulted in very poor model statistics, possibly owing to the limited range of activity measured and the fact that the data corresponded to a functional response that is likely more complex ([Brea *et al*., 2002](#bib10){ref-type="other"}). Neither of these models was validated with external predictions. On the basis of bacteriorhodopsin and rhodopsin, homology models for the mouse and human 5-HT~2B~ receptor have been combined with site-directed mutagenesis. The bacteriorhodopsin structure provided more reliable models, which confirmed an aromatic box hypothesis for ligand interaction along transmembrane domains 3, 6, 7 with serotonin ([Manivet *et al*., 2002](#bib98){ref-type="other"}). A more recent 5-HT~2B~ homology model based on the rhodopsin-based model of the rat 5-HT~2A~ was used to determine the sites of interaction for norfenfluramine following molecular dynamics simulations. Site-directed mutagenesis showed that Val 2.53 was implicated in high-affinity binding through van der Waals interactions and the ligand methyl groups ([Setola *et al*., 2005](#bib129){ref-type="other"}). There is certainly an opportunity to develop further QSAR models for this receptor in order to rapidly screen libraries of molecules to identify undesirable potent inhibitors.

The serotonin 5-HT~1A~ receptor has been frequently modelled. For example, a conformational study of four ligands defined a pharmacophore of the antagonist site using SYBYL ([Hibert *et al*., 1988](#bib61){ref-type="other"}). The model resulting from such an active analogue approach was used in molecule design and predicted molecule stereospecificity. More recently, a series of over 700 homology models were iteratively created based on the crystal structure of the bovine rhodopsin that were in turn tuned by FlexX docking of known ligands. The final model was used in a virtual screening simulation that was enriched with inhibitors, compared with random selection and from this the authors suggested its utility for a real virtual screen ([Nowak *et al*., 2006](#bib111){ref-type="other"}). A homology model of the 5-HT~1A~ receptor has also been used with DOCK to screen a library of 10 000 compounds seeded with 34 5-HT~1A~ ligands. Ninety percent of these active compounds were ranked in the top 1000 compounds ([Becker *et al*., 2006](#bib7){ref-type="other"}), representing a significant enrichment. The same model was used to screen a library of 40 000 vendor compounds and select 78 for testing, of which 16 had activities below 5 *μ*[M]{.smallcaps}, one possessing 1 n[M]{.smallcaps} affinity. Structure-based *in silico* optimization was then performed to improve selectivity with other GPCRs and optimize the pharmacokinetic (PK) profile. However, as this proceeded, the molecules were found to have affinity for the human ether a-go-go-related gene (hERG), and this was subsequently computationally assessed using a homology model that pointed to adjusting the hydrophobicity. The resulting clinical candidate had good target and antitarget selectivity and backup compounds were selected in the same way ([Becker *et al*., 2006](#bib7){ref-type="other"}).

Another early computer-aided pharmacophore generated with SYBYL using a set of selective and non-selective analogues was used to design agonists for 5-HT~1D~ as antimigraine agents with selectivity against 5-HT~2A~ (linked to undesirable changes in blood pressure) ([Glen *et al*., 1995](#bib51){ref-type="other"}).

A range of typical and atypical antipsychotics bind to the 5-HT~6~ receptor. Based on the structure of bovine rhodopsin, homology models of the human and rodent 5-HT~6~ receptors were constructed and used to dock ligands that were known to exhibit species differences in binding ([Hirst *et al*., 2003](#bib63){ref-type="other"}). Following sequence alignment, amino-acid residues were identified for mutation and the rationalization of these mutations and their effects on ligand binding were obtained from the docking studies. The models generated were in good agreement with the *in vitro* data and could be used for further molecule design. This study was a good example where computational, molecular biology and traditional pharmacology methods were combined ([Hirst *et al*., 2003](#bib63){ref-type="other"}).

The Na^+^, K^+^-ATPase is a receptor for cardiotonic steroids, which in turn inhibit the ATPase and cation transport and have ionotropic actions. Although the effects of digitalis have been known for hundreds of years, a molecular understanding has remained absent until recently. A homology model was generated with the SERCA1a crystal structure and tested with nine cardiac glycosides ([Keenan *et al*., 2005](#bib74){ref-type="other"}). The model was also mutated to mimic the rat receptor and showed how oubain would orient differently in these models, perhaps explaining the species difference in affinity. These models also suggested amino acids that could be experimentally mutated to validate the hypothesis for the binding site identification, although this has yet to be tested.

The dopamine receptors have been implicated in Parkinson\'s disease and schizophrenia. Unfortunately, no crystal structure is currently available and thus the search for new antagonists has used QSAR models. A set of 48 compounds was used with four different QSAR methods (CoMFA, simulated annealing-partial least square (PLS), *k*-nearest neighbours (kNN) and SVM), and training as well as testing statistics were generated. SVM and kNN models were also used to mine compound databases of over 750 000 molecules that resulted in 54 consensus hits. Five of these hits were known to bind the receptor and were not in the training set, while other suggested hits did not contain the catechol group normally seen in most dopamine inhibitors ([Oloff *et al*., 2005](#bib114){ref-type="other"}).

The *α*1A receptor is a target for controlling vascular tone and therefore useful for antihypertensive agents. A novel approach for ligand-based screening called multiple feature tree (MTree) describes the training set molecules as a feature tree descriptor derived from a topological molecular graph that is then aligned in a pairwise fashion ([Hessler *et al*., 2005](#bib60){ref-type="other"}). A set of six antagonists was used to derive a model with this method and was compared with a Catalyst pharmacophore model. Both approaches identified a central positive ionizable feature flanked by hydrophobic regions at either end. These two methods were compared for their ability to rank a database of over 47 000 molecules. Within the top 1% of the database, MTree had an enrichment factor that was over twice that obtained with Catalyst ([Hessler *et al*., 2005](#bib60){ref-type="other"}).

### Nuclear receptors:

Nuclear receptors constitute a family of ligand-activated transcription factors of paramount importance for the pharmaceutical industry since many of its members are often considered as double-edged swords ([Shi, 2006](#bib133){ref-type="other"}). On the one hand, because of their important regulatory role in a variety of biological processes, mutations in nuclear receptors are associated with many common human diseases such as cancer, diabetes and osteoporosis and thus, they are also considered highly relevant therapeutic targets. On the other hand, nuclear receptors act also as regulators of some the CYP enzymes responsible for the metabolism of pharmaceutically relevant molecules, as well as transporters that can mediate drug efflux, and thus they are also regarded as potential therapeutic antitargets (off-targets).

Examples of the use of target-based virtual screening to identify novel small molecule modulators of nuclear receptors have been recently reported. Using the available structure of the oestrogen receptor subtype *α* (ER*α*) in its antagonist conformation, a homology model of the retinoic acid receptor *α* (RAR*α*) was constructed ([Schapira *et al*., 2000](#bib125){ref-type="other"}). Using this homology model, virtual screening of a compound library lead to the identification of two novel RAR*α* antagonists in the micromolar range. The same approach was later applied to discover 14 novel and diverse micromolar antagonists of the thyroid hormone receptor ([Schapira *et al*., 2000](#bib125){ref-type="other"}). By means of a procedure designed particularly to select compounds fitting onto the LxxLL peptide-binding surface of the oestrogen receptor, novel ER*α* antagonists were identified ([Shao *et al*., 2004](#bib130){ref-type="other"}). Since poor displacement of 17*β*-estradiol was observed in the ER-ligand competition assay, these compounds may represent new classes of ER*α* antagonists, with the potential to provide an alternative to current anti-oestrogen therapies. The discovery of three low micromolar hits for ER*β* displaying over 100-fold binding selectivity with respect to ER*α* was also recently reported using database screening ([Zhao and Brinton, 2005](#bib170){ref-type="other"}). A final example reports the identification and optimization of a novel family of peroxisome proliferator-activated receptors-*γ* partial agonists based upon pyrazol-4-ylbenzenesulfonamide after employing structure-based virtual screening, with good selectivity profile against the other subtypes of the same nuclear receptor group ([Lu *et al*., 2006](#bib96){ref-type="other"}).

### Ion channels:

Therapeutically important channels include voltage-gated ion channels for potassium, sodium and calcium that are present in the outer membrane of many different cells such as those responsible for the electrical excitability and signalling in nerve and muscle cells ([Terlau and Stuhmer, 1998](#bib149){ref-type="other"}). These represent validated therapeutic targets for anaesthesia, CNS and cardiovascular diseases ([Kang *et al*., 2001](#bib69){ref-type="other"}). A recent review has discussed the various QSAR methods such as pharmacophores, CoMFA, SVM, 2D-QSAR, Genetic Programming, Self Organizing Maps and recursive partitioning that have been applied to most ion channels ([Aronov *et al*., 2006](#bib2){ref-type="other"}) in the absence of crystal structures. To date [L]{.smallcaps}-type calcium channels and hERG appear to have been the most extensively studied channels in this regard. In contrast, there are far fewer examples of computational models for the sodium channel. These three classes of ion channels have been studied as they represent either therapeutic targets or antitargets to be avoided.

For example, one of many models for the hERG potassium channel has compared three different methods with the same set of molecules for training and a test set. Recursive partitioning, Sammon maps and Kohonen maps were used with atom path lengths ([Ekins *et al*., 2006](#bib29){ref-type="other"}). The average classification quality was high for both training and test selections. The Sammon mapping technique outperformed the Kohonen maps in classification of compounds from the external test set. The quantitative predictions for recursive partitioning could be filtered using a Tanimoto similarity to remove molecules that were markedly different to the training set ([Willett, 2003](#bib163){ref-type="other"}). The path length descriptors can also be used to visualize the similarity of the molecules in the whole training set ([Figure 1a](#fig1){ref-type="fig"}). In addition, a subset of molecules can also be compared, with those highlighted in blue representing close neighbours and those in red being more distant ([Figure 1b](#fig1){ref-type="fig"}).

### Transcription factors:

A cyclic decapeptide with activity against the AP-1 transcription factor was used to derive a 3D pharmacophore to which low energy conformations of non-peptidic compounds were compared. New 1-thia-4-azaspiro\[4,5\]decane and benzophenone derivatives with activity in binding and cell-based assays were discovered as AP-1 inhibitors in a lead hopping approach ([Tsuchida *et al*., 2006](#bib155){ref-type="other"}).

### Antibacterials:

Twenty deoxythymidine monophosphate analogues were used along with docking to generate a pharmacophore for *Mycobacterium tuberculosis* thymidine monophosphosphate kinase inhibitors with the Catalyst software. A final model was used to screen a large database spiked with known inhibitors. The model was suggested to have an enrichment factor of 17, which is highly significant. In addition, the model was used to rapidly screen half a million compounds in an effort to discover new inhibitors ([Gopalakrishnan *et al*., 2005](#bib53){ref-type="other"}).

### Antivirals:

Neuroamidase is a major surface protein in influenza virus. A structure-based approach was used to generate Catalyst pharmacophores and these in turn were used for a database search and aided the discovery of known inhibitors. The hit lists were also very selective ([Steindl and Langer, 2004](#bib145){ref-type="other"}).

Human rhinovirus 3C protease is an antirhinitis target. A structure-based pharmacophore was developed initially around AG 7088 but this proved too restrictive. A second pharmacophore was developed from seven peptidic inhibitors using the Catalyst HIPHOP method. This hypothesis was useful in searching the world drug index database to retrieve compounds with known antiviral activity and several novel compounds were selected from other databases with good fits to the pharmacophore, indicative that they would be worth testing although these ultimate testing validation data were not presented ([Steindl *et al*., 2005a](#bib144){ref-type="other"}). Human rhinovirus coat protein is another target for antirhinitis. A combined pharmacophore, docking approach and PCA-based clustering was used. A pharmacophore was generated from the structure and shape of a known inhibitor and tested for its ability to find known inhibitors in a database. Ultimately, after screening the Maybridge database, 10 compounds were suggested that were then docked and scored. Six compounds were tested and found to inhibit viral growth. However, the majority of them were found to be cytotoxic or had poor solubility ([Steindl *et al*., 2005b](#bib146){ref-type="other"}). The Ligand Scout approach was tested on the rhinovirus serotype 16 and was able to find known inhibitors in the PDB ([Wolber and Langer, 2005](#bib165){ref-type="other"}).

The SARS coronavirus 3C-like proteinase has been addressed as a potential drug design target. A homology model was built and chemical databases were docked into it. A pharmacophore model and drug-like rules were used to narrow the hit list. Forty compounds were tested and three were found with micromolar activity, the best being calmidazolium at 61 *μ*[M]{.smallcaps} ([Liu *et al*., 2005](#bib90){ref-type="other"}), perhaps a starting point for further optimization.

A pharmacophore has also been developed to predict the hepatitis C virus RNA-dependent RNA polymerase inhibition of diketo acid derivatives. A Catalyst HypoGen model was derived with 40 molecules with activities over three log orders to result in a five-feature pharmacophore model. This was in turn tested with 19 compounds from the same data set as well as nine diketo acid derivatives, for which the predicted and experimental data were in good agreement ([Di Santo *et al*., 2005](#bib25){ref-type="other"}).

### Other therapeutic targets:

The integrin VLA-4 (*α*4*β*1) is a target for autoimmune and inflammatory diseases such as asthma and rheumatoid arthritis. The search for antagonists has included using a Catalyst pharmacophore derived from the X-ray crystal structure of a peptidic inhibitor ([Singh *et al*., 2002b](#bib136){ref-type="other"}). This was used to search a virtual database of compounds that could be made with reagents from the available chemicals directory. Twelve compounds were then selected and synthesized, with resulting activities in the range between 1.3 n[M]{.smallcaps} and 20 *μ*[M]{.smallcaps}. Hence, a peptide was used to derive non-peptide inhibitors that were active *in vivo*. A second study by the same group used CoMFA with a set of 29 antagonists with activity from 1 to 662 n[M]{.smallcaps} to generate a model with good internal validation statistics that was subsequently used to indicate favourable regions for molecule substituent changes ([Singh *et al*., 2002a](#bib135){ref-type="other"}). It is unclear whether the CoMFA model was also successful for design of further molecules.

It is possible to use approved drugs as a starting point for drug discovery for other diseases. For example, the list of World Health Organization essential drugs has been searched to try to find leads for prion diseases using 2D Tanimoto similarity or 3D searching with known inhibitors. This work to date has suggested compounds, yet they appear not to have been tested, so the approach has not been completely validated ([Lorenzen *et al*., 2005](#bib95){ref-type="other"}).

Protein--protein interactions are key components of cellular signalling cascades, the selective interruption of which would represent a sought after therapeutic mechanism to modulate various diseases ([Tesmer, 2006](#bib151){ref-type="other"}). However, such pharmacological targets have been difficult for *in silico* methods to derive small molecule inhibitors owing to generally quite shallow binding sites. The G-protein G*βγ* complex can regulate a number of signalling proteins via protein--protein interactions. The search for small molecules to interfere with the G*βγ*-protein--protein interaction has been targeted using FlexX docking and consensus scoring of 1990 molecules from the NCI diversity set database ([Bonacci *et al*., 2006](#bib9){ref-type="other"}). After testing 85 compounds as inhibitors of the G*β*~1~*γ*~2~-SIRK peptide, nine compounds were identified with IC~50~ values from 100 n[M]{.smallcaps} to 60 *μ*[M]{.smallcaps}. Further substructure searching was used to identify similar compounds to one of the most potent inhibitors to build a SAR. These efforts may eventually lead to more potent lead compounds.

Complex property modelling
--------------------------

Up to this point, we have generally considered *in silico* pharmacology models that essentially relate to a single target protein and either the discovery of molecules as agonists, antagonists or with other biological activity after database searching and *in vitro* testing or following searching of databases seeded with molecules of known activity for the target. However, there are many complex properties that have been modelled *in silico* and these will be briefly discussed here. It should also be pointed out that while several physicochemical properties such as ClogP and water solubility have been extensively studied, the training sets for these models are in the 1000s or tens of thousands of molecules, while other complex properties have generally used much smaller training sets in the range of hundreds of molecules.

For example, a measure of molecule clearance would be indicative of elimination half-life that would naturally be of value for selecting candidates. The intrinsic clearance has therefore been used as a measure of the enzyme activity toward a compound and this may involve multiple enzymes. Some of the earliest models for this property includes a CoMFA model of the CYP-mediated metabolism of chlorinated volatile organic compounds, likely representative of CYP2E1 ([Waller *et al*., 1996](#bib160){ref-type="other"}). A more generic set of molecules with clearance data derived from human hepatocytes has been used to predict human *in vivo* clearance using multiple linear regression, PCA, PLS, Neural Networks with leave-one-out cross-validation ([Schneider *et al*., 1999](#bib126){ref-type="other"}). Microsomal and hepatocyte clearance data sets have also been used separately to generate Catalyst pharmacophores, which were then tested by predicting the opposing data set. This method assumes there are some pharmacophore features intrinsic to the molecules that dictate intrinsic clearance ([Ekins and Obach, 2000](#bib35){ref-type="other"}).

A second complex property is the volume of distribution that is a function of the extent of drug partitioning into tissue versus plasma and there have been several attempts at modelling this property ([Lombardo *et al*., 2002](#bib94){ref-type="other"}, [2004](#bib93){ref-type="other"}). This property, along with the plasma half-life, determines the appropriate dose of a drug. For example, 253 diverse drugs from the literature were used with eight molecular descriptors with Sammon and Kohonen mapping methods. These models appeared to classify correctly 80% of the compounds ([Balakin *et al*., 2005](#bib4){ref-type="other"}). Recently, a set of 384 drugs with literature volume of distribution at steady-state data was used with a mixture discriminant analysis-random forest method and 31 molecular descriptors to generate a predictive model. This model was tested with 23 molecules, resulting in a geometric mean fold error of 1.78, which was comparable to the values for other predictions for this property from animal, *in vitro*, or other methods ([Lombardo *et al*., 2006](#bib92){ref-type="other"}).

A third property, the plasma half-life determined by numerous ADME properties has also been modelled with Sammon and Kohonen maps using data for 458 drugs from the literature and four molecular descriptors. Like the previously described volume of distribution models, these models appeared to classify correctly 80% of the compounds ([Balakin *et al*., 2005](#bib4){ref-type="other"}).

A fourth complex property is renal clearance, which assumes the excretion of the unchanged drug that takes place only by this route, hence this represents a method of monitoring the proportion of drug metabolized. In one set of published QSAR models, 130 molecules were used with 62 Volsurf or 37 Molconn-Z descriptors. The models were tested with 20 molecules and one using soft independent modelling of class analogies and Molconn-Z descriptors obtained 85% correct classification between the two classes (0--20 and 20--100%) ([Doddareddy *et al*., 2006](#bib27){ref-type="other"}).

A fifth example of a complex property is the protein--ligand interaction and appropriate scoring functions for which several methods have been developed such as force fields, empirical and knowledge-based approaches (see also [Ekins *et al*., 2007](#bib33){ref-type="other"}). These are important in computational structure-based design methods for assessing virtual candidate molecules to select those that are likely to bind a protein with highest affinity ([Shimada, 2006](#bib134){ref-type="other"}). Recently, a Kernel partial least squares (K-PLSs) QSAR approach has been used along with a genetic algorithm feature selection method for the distance-dependent atom pair descriptors from the 61 or 105 small molecule training sets with binding affinity data and the proteins they bind to. Bootstrapping, scrambling the data and external test sets were used to test the models ([Deng *et al*., 2004](#bib24){ref-type="other"}). In essence, such K-PLS QSAR models across many proteins perhaps isolate the key molecular descriptors that relate to the highest affinity interactions. It will be interesting to see whether such models can continue to be generated with the much larger binding affinity data sets that are now available.

A final example of a complex property is the *V*~max~ of an enzyme that has been modelled on a few occasions ([Hirashima *et al*., 1997](#bib62){ref-type="other"}; [Mager *et al*., 1982](#bib97){ref-type="other"}; [Ghafourian and Rashidi, 2001](#bib50){ref-type="other"}; [Sipila and Taskinen, 2004](#bib138){ref-type="other"}). This value will depend on the properties of the compound in question and will be influenced by the steric properties of the active site as well as the ease of expulsion of the leaving group from the active site. [Balakin *et al*. (2004)](#bib3){ref-type="other"}, have recently used neural network methods to model the *V*~max~ data for *N*-dealkylation mediated by CYP2D6 and CYP3A4, using whole molecules, centroid of the reaction and leaving group-related descriptors. These models were also used to predict small sets of molecules not included in training. Ultimately, many other reactions and the evaluation of other enzymes will be necessary. Similarly, larger test sets are required for all the above complex property models to provide further confidence in the models in terms of their utility and applicability.

Current scope, limitations, and trends
======================================

Uses of *in silico* pharmacology
--------------------------------

We propose a general schema for *in silico* pharmacology, which is shown in [Figure 2](#fig2){ref-type="fig"}. This demonstrates some of the key roles of the computational technologies that can assist pharmacology. These roles include finding new antagonists or agonists for a target using an array of methods either in the absence or presence of a structure for the target. Computational methods may also aid in understanding the underlying biology using network/pathways based on annotated data (signalling cascades), determining the connectivity of drug as a network with targets to understand selectivity, integration with other models for PK/PD (pharmacodynamic) and ultimately the emergence of systems *in silico* pharmacology. Obviously, we have taken more of a pharmaceutical bias in this review but we would argue these methods are equally amenable and should be considered to discover new chemical probes for the academic pharmacologist as opposed to lead molecules for optimization to become drugs. Some of the advantages of *in silico* pharmacology and *in silico* methods in general are the reduction in the number of molecules made and tested through database searching to find inhibitors or substrates, increased speed of experiments through reliable prediction of most pharmaceutical properties from molecule structure alone and ultimately reductions in animal and reagent use. We must however consider the multiple optimization of numerous predicted properties, possibly either weighting *in silico* pharmacology models by importance (or confidence in the model and or data), as well as data set size and diversity. Similarly, we should consider the disadvantages of *in silico* pharmacology methods as protein flexibility, molecule conformation and promiscuity all hinder accurate predictions. For example, even with the recent availability of crystal structures for several mammalian drug-metabolizing enzymes, there is still considerable difficulty in reliable metabolism predictions. Our focus thus far has been on the creation of many *in silico* pharmacology models for human properties, yet as pharmacology uses animals for much *in vivo* testing and subcellular preparations from several species for *in vitro* experiments, we need models from other species both to understand differences as well as enable better scaling between them. A widely discussed disadvantage of *in silico* methods is the applicability of the model, which will now be discussed further.

Defining *in silico* model applicability domain
-----------------------------------------------

Some of the *in silico* pharmacology methods that can be used have similar limitations to models used in other areas, such as those for predicting physicochemical and ADME/Tox properties. For example, models may be generated with a narrow homologous series of pharmacologically relevant molecules (local model) or a structurally diverse range of molecules (global model). These two approaches have their pros and cons, respectively. The applicability domain of the local model may be much narrower than for the global model such that changing to a new chemical series will result in prediction failure. However, global models may also fail if the predicted molecule falls far enough away from representative molecules in the training set. These limitations are particularly specific to QSAR models. From many of the *in silico* pharmacology model examples described above, the QSAR models are generally local in nature and this will limit lead hopping to new structural series, whereas global models may be more useful for this feature. Several papers have described the applicability domain of models and methods in considerable detail ([Dimitrov *et al*., 2005](#bib26){ref-type="other"}; [Tetko *et al*., 2006](#bib153){ref-type="other"}) to calculate this property. Molecular similarity to training set compounds may be a reliable measure for prediction quality ([Sheridan *et al*., 2004](#bib132){ref-type="other"}) as demonstrated for a hERG model ([Ekins *et al*., 2006](#bib29){ref-type="other"}). To our knowledge, there has not been a specific analysis of the applicability domain specifically for *in silico* pharmacology models (other than for those examples described above) to the same degree as there has been for physicochemical properties like solubility and logP. The applicability domain of pharmacophore models have not been addressed either as the focus has primarily been on statistical QSAR methods.

As we shift toward hybrid or meta-computational methods (that integrate several modelling approaches and algorithms) for predicting from molecular structure the possible physicochemical and pharmacological properties, then these could be used to provide prediction confidence by consensus. The docking methods with homology models for certain proteins of pharmacological interest could be used alongside QSAR or pharmacophore models if these are also available. There have been numerous occasions in the study of drug-metabolizing enzymes were QSAR and homology models have been combined or used to validate each other ([de Groot *et al*., 2002a](#bib21){ref-type="other"}; [de Graaf *et al*., 2005](#bib19){ref-type="other"}; [de Groot, 2006](#bib20){ref-type="other"}).

Drug metabolism is a good example as several simultaneous outcomes (for example, metabolites) often occur, a condition not normally found in other pharmacological assays where a single set of conditions yields a single outcome. It is here that the classification into specific ('local\') and comprehensive ('global\') methods finds its clearest use (see [Figure 3](#fig3){ref-type="fig"}), with local methods being applicable to simple biological systems such as a single enzyme or a single enzymatic activity ([Testa and Krämer, 2006](#bib152){ref-type="other"}). The production of regioselective metabolites (for example, hydroxylation to a phenol and an alcohol) is usually predictable from such methods, but that of different routes (for example, oxidation versus glucuronidation) is not. This is where global algorithms (that is, applicable to versatile biological systems) are most useful in their potential capacity to encompass all or most metabolic reactions and offer predictions, which are much closer to the *in vivo* situation.

Observations and caveats
------------------------

It is readily apparent that in a minority of papers we have found that computational approaches have resulted in predicted lead compounds for testing without the authors providing further experimental verification of biological activity ([Krovat and Langer, 2004](#bib80){ref-type="other"}; [Langer *et al*., 2004](#bib85){ref-type="other"}; [Steindl and Langer, 2004](#bib145){ref-type="other"}; [Gopalakrishnan *et al*., 2005](#bib53){ref-type="other"}; [Lorenzen *et al*., 2005](#bib95){ref-type="other"}; [Steindl *et al*., 2005a](#bib144){ref-type="other"}; [Amin and Welsh, 2006](#bib1){ref-type="other"}). This is an interesting observation as for many years computational studies were generally performed after synthesis of molecules, and essentially provided illustrative pictures and explanation of the data. Now it appears we are seeing a shift in the other direction as predictions are published for pharmacological activity without apparently requiring *in vitro* or *in vivo* experimental verification, as long as the models themselves are validated in some manner. As the models may only have a limited prediction domain so perhaps in future we will see some discussion of the predicted molecules and their distance from the training set or some other measure of how far the predictions can be extended.

Many of the molecules identified by virtual screening techniques have not been tested *in vitro* to ensure that they are not false positives that may actually be involved in molecule aggregation. These types of molecules have been termed so-called 'promiscuous inhibitors\', occurring as micromolar inhibitors of several proteins ([McGovern *et al*., 2002](#bib101){ref-type="other"}; [McGovern and Shoichet, 2003](#bib102){ref-type="other"}; [Seidler *et al*., 2003](#bib128){ref-type="other"}). A preliminary computational model was developed to help identify these potential promiscuous inhibitors ([Seidler *et al*., 2003](#bib128){ref-type="other"}). From reviewing the literature, we suggest it would be worth researchers either implementing filters for 'promiscuous inhibitors\' or performing rigorous experimental verification of their predicted bioactive molecules to rule out this possibility.

Publication bias perhaps also limits the number of examples of failures of computational methods that are published (if any). It would certainly be very useful to know the existence of difficult targets for modelling with different methods, as this apparently is a process of trial and error for each investigator currently.

In summary, in this and the accompanying review ([Ekins *et al*., 2007](#bib33){ref-type="other"}), we have presented our interpretation of *in silico* pharmacology and described how the field has developed so far and is used for: discovery of molecules that bind to many different targets and display bioactivity, prediction of complex properties and the understanding of the underlying metabolic and network interactions. While we have not explicitly discussed PK/PD, whole organ, cell or disease simulations in this review, we recognize they too are an important component of the computer-aided drug design approach ([Noble and Colatsky, 2000](#bib110){ref-type="other"}; [Gomeni *et al*., 2001](#bib52){ref-type="other"}; [Kansal, 2004](#bib70){ref-type="other"}) and may be more widely integrated with other *in silico* pharmacology methods described previously ([Ekins *et al*., 2005](#bib34){ref-type="other"}).

Conclusion
==========

The brief history of *in silico* pharmacology has taken perhaps a rather predictable route with computational models applied to many of the most important biological targets where they have the capacity to be used to search large databases and quickly suggest molecules for testing. Many of the examples we have presented have demonstrated significant enrichments over random selection of molecules and so far these have been the most plentiful types of metrics that are routinely used to validate *in silico* models. The future of *in silico* pharmacology may be somewhat difficult to predict. While we are seeing a closer interaction between computational and *in vitro* approaches to date, will we see a similar relationship with *in vivo* studies in the future? More broadly, will *in silico* pharmacology ever be able to replace entirely experimental approaches *in vitro* and even *in vivo*, as some animal rights activists want us to believe? The answer here can only be a clear and resounding 'no\' (at least in the near future), for two irrefutable reasons. First, biological entities are nonlinear systems showing 'chaotic behaviour\'. As such, there is no relation between the magnitude of the input and the magnitude of the output, with even the most minuscule differences between initial conditions rapidly translating into major differences in the output. And second, no computer programme, however 'complex and systems-like\', will ever be able to fully model the complexity of biological systems. Indeed, and in the formulation of the mathematician Gregory Chaitin, biological systems are algorithmically incompressible, meaning that they cannot be modelled fully by an algorithm shorter than themselves.

In the meantime, *in silico* pharmacology will likely become more complex requiring some degree of integration of models, as we are seeing in the combined metabolism modelling approaches ([Figure 3](#fig3){ref-type="fig"}). Ultimately, to have a much broader impact, the *in silico* tools will need to become a part of every pharmacologist\'s tool kit and this will require training in modelling and informatics, alongside the *in vivo*, *in vitro* and molecular skills. This should provide a realistic appreciation of what the different *in silico* methods can and cannot be expected to do with regard to the pharmacologists aim of discovering new therapeutics.
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![(**a**) A distance matrix plot of the 99 molecule hERG training set showing in general that the molecules are globally dissimilar as the plot is primarily red ([Ekins *et al*., 2006](#bib29){ref-type="other"}). (**b**) A distance matrix plot of a subset of the training set to show molecules similar to astemizole. Blue represents close molecules and red represents distant molecules based on the ChemTree pathlength descriptors (see colour scale).](0707306f1){#fig1}

![A schematic for *in silico* pharmacology.](0707306f2){#fig2}

![Local and global models applied to drug metabolism. Figures are taken from [Testa and Krämer (2006)](#bib152){ref-type="other"} with permission.](0707306f3){#fig3}

###### 

A broad selection of *in silico* pharmacology targets that have been used with computational methods to discover new molecules with binding affinity

  *Target class*              *Target name*                                                     *Reference*
  --------------------------- ----------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Enzyme                      Farnesyl transferase                                              [Kaminski *et al*. (1997)](#bib68){ref-type="other"}
                              Thrombin                                                          [Srinivasen *et al*. (2002)](#bib142){ref-type="other"}
                              Acetylcholinesterase                                              [Sippl (2002)](#bib139){ref-type="other"}, [Rollinger *et al*. (2004)](#bib121){ref-type="other"}
                              Protein-tyrosine-phosphatase 1B                                   [Doman *et al*. (2002)](#bib28){ref-type="other"}, [Sippl (2002)](#bib139){ref-type="other"}
                              Factor-Xa                                                         [O\'Brien *et al*. (2005)](#bib112){ref-type="other"}
                              Ubiquitin isopeptidase                                            [Mullally *et al*. (2001)](#bib105){ref-type="other"}, [Mullally and Fitzpatrick (2002)](#bib104){ref-type="other"}
                              Aromatase (CYP19)                                                 [Schuster *et al*. (2006)](#bib127){ref-type="other"}
                              COX-1, COX-2                                                      [Rollinger *et al*. (2005)](#bib120){ref-type="other"}
                              LOX                                                               [Charlier *et al*. (2006)](#bib16){ref-type="other"}
                              12-LOX and 15-LOX                                                 [Kenyon *et al*. (2006)](#bib75){ref-type="other"}
                              Renin                                                             [Van Drie (1993)](#bib156){ref-type="other"}, [Khadikar *et al*. (2005)](#bib76){ref-type="other"}, [Bursavich and Rich (2002)](#bib11){ref-type="other"}, [Krovat and Langer (2004)](#bib80){ref-type="other"}, [Hert *et al*. (2004)](#bib59){ref-type="other"}
                              Cathepsin D                                                       [Kick *et al*. (1997)](#bib77){ref-type="other"}, [Pegg *et al*. (2001)](#bib116){ref-type="other"}, [Huo *et al*. (2002)](#bib66){ref-type="other"}, [Ekins *et al*. (2004a)](#bib30){ref-type="other"}
                              Glycogen phosphorylase                                            [Klabunde *et al*. (2005)](#bib78){ref-type="other"}
                              Sirtuin type 2                                                    [Tervo *et al*. (2004)](#bib150){ref-type="other"}
                                                                                                 
  Drug metabolizing enzymes   Catechol *O*-methyltransferase                                    [Chen *et al*. (2005)](#bib17){ref-type="other"}
                              Cytochrome *P*450s                                                [de Groot and Ekins (2002b)](#bib22){ref-type="other"}, [de Graaf *et al*. (2005)](#bib19){ref-type="other"}, [de Groot (2006)](#bib20){ref-type="other"}, [Lill *et al*. (2006)](#bib89){ref-type="other"}
                              UDP-glucuronosyltransferases                                      [Smith *et al*. (2004)](#bib140){ref-type="other"}, [Sorich *et al*. (2004)](#bib141){ref-type="other"}
                              Sulfotransferases                                                 [Dajani *et al*. (1999)](#bib18){ref-type="other"}
                                                                                                 
  Kinases                     Protein kinase C                                                  [Wang *et al*. (1994)](#bib161){ref-type="other"}
                              CDK1                                                              [Furet *et al*. (2000)](#bib47){ref-type="other"}, [Kunick *et al*. (2005)](#bib82){ref-type="other"}
                              Syk C-terminal SH2 domain                                         [Niimi *et al*. (2001)](#bib108){ref-type="other"}
                              EFGR tyrosine kinase                                              [Peng *et al*. (2003)](#bib117){ref-type="other"}
                              Lck SH2 domain                                                    [Huang *et al*. (2004)](#bib65){ref-type="other"}
                              ERK2                                                              [Hancock *et al*. (2005)](#bib57){ref-type="other"}
                              BCR-ABL tyrosine kinase                                           [Wolber and Langer (2005)](#bib165){ref-type="other"}
                              CK2 and PKD                                                       [Fullbeck *et al*. (2005)](#bib46){ref-type="other"}
                                                                                                 
  Transporter                 Na^+^/[D]{.smallcaps}-glucose co-transporter                      [Wielert-Badt *et al*. (2000)](#bib162){ref-type="other"}
                              ADME-related (for example P-gp)                                   [Chang and Swaan (2005)](#bib15){ref-type="other"}, [Zhang *et al*. (2002a)](#bib168){ref-type="other"}, [Zhang *et al*. (2002b)](#bib169){ref-type="other"}
                                                                                                 
  Receptor                    Endothelial differentiation gene receptor antagonists             [Koide *et al*. (2002)](#bib79){ref-type="other"}
                              Urotensin antagonists                                             [Flohr *et al*. (2002)](#bib44){ref-type="other"}
                              CCR5 antagonist                                                   [Debnath (2003)](#bib23){ref-type="other"}
                              Oestrogen receptor                                                [Sippl (2002)](#bib139){ref-type="other"}
                              AMPA receptor                                                     [Barreca *et al*. (2003)](#bib6){ref-type="other"}
                              5-HT~2B~                                                          [Singh and Kumar (2001)](#bib137){ref-type="other"}, [Brea *et al*. (2002)](#bib10){ref-type="other"}, [Manivet *et al*. (2002)](#bib98){ref-type="other"}, [Setola *et al*. (2005)](#bib129){ref-type="other"}
                              5-HT~1A~                                                          [Hibert *et al*. (1988)](#bib61){ref-type="other"}, [Nowak *et al*. (2006)](#bib111){ref-type="other"}, [Becker *et al*. (2006)](#bib7){ref-type="other"}
                              5-HT~1D~                                                          [Glen *et al*. (1995)](#bib51){ref-type="other"}
                              5-HT~6~                                                           [Hirst *et al*. (2003)](#bib63){ref-type="other"}
                              Na^+^, K^+^-ATPase                                                [Keenan *et al*. (2005)](#bib74){ref-type="other"}
                              Dopamine                                                          [Oloff *et al*. (2005)](#bib114){ref-type="other"}
                              *α*1A                                                             [Hessler *et al*. (2005)](#bib60){ref-type="other"}
  Channels                    Potassium, sodium and calcium                                     Reviewed by [Aronov *et al*. (2006)](#bib2){ref-type="other"}
                                                                                                 
  Transcription factors       AP-1 transcription factor                                         [Tsuchida *et al*. (2006)](#bib155){ref-type="other"}
                                                                                                 
  Other therapeutic targets   Mesangial cell proliferation inhibitor                            [Kurogi *et al*. (2001b)](#bib84){ref-type="other"}
                              Prion diseases                                                    [Lorenzen *et al*. (2005)](#bib95){ref-type="other"}
                              G*βγ*-protein--protein interaction                                [Bonacci *et al*. (2006)](#bib9){ref-type="other"}
                              Integrin VLA-4 (*α*4*β*1)                                         [Singh *et al*. (2002b)](#bib136){ref-type="other"}, [Singh *et al*. (2002a)](#bib135){ref-type="other"}
                                                                                                 
  Antibacterial               *Mycobacterium tuberculosis* thymidine monophosphosphate kinase   [Gopalakrishnan *et al*. (2005)](#bib53){ref-type="other"}
                                                                                                 
  Antiviral                   HIV integrase                                                     [Carlson *et al*. (2000)](#bib12){ref-type="other"}, [Nicklaus *et al*. (1997)](#bib107){ref-type="other"}
                              HIV-1 reverse transcriptase                                       [Griffith *et al*. (2005)](#bib54){ref-type="other"}, [O\'Brien *et al*. (2005)](#bib112){ref-type="other"}
                              Neuroamidase                                                      [Steindl and Langer (2004)](#bib145){ref-type="other"}
                              Human rhinovirus 3C protease                                      [Steindl *et al*. (2005a)](#bib144){ref-type="other"}
                              Human rhinovirus coat protein                                     [Steindl *et al*. (2005b)](#bib146){ref-type="other"}
                              Rhinovirus serotype 16                                            [Wolber and Langer (2005)](#bib165){ref-type="other"}
                              SARS coronavirus 3C-like proteinase                               [Liu *et al*. (2005)](#bib90){ref-type="other"}
                              Hepatitis C virus RNA-dependent RNA polymerase                    [Di Santo *et al*. (2005)](#bib25){ref-type="other"}

Abbreviations: AMPA, *α*-amino-3-hydroxy-5-methyl-4-isoxazole propionate; COX, cyclooxygenase; CYP, cytochrome *P*450; HIV-1, human immunodeficiency virus; LOX, 5 lipoxygenase.
